Aim: Data from 69 well-differentiated gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionucleotide therapy + somatostatin analogs (SSAs) after SSA treatment failure were evaluated. Methods: We identified two groups: S1 - patients who kept the same SSA treatment beyond progression; S2 - patients who switched the SSA with another SSA after progression. Results: Median progression-free survival was 53 and 127 months in S1 and S2, respectively (p = 0.001; hazard ratio: 0.31; 95% CI: 0.15-0.63). Median overall survival was 69 versus 150 months in S1 and S2, respectively (p = 0.004; hazard ratio: 0.32; 95% CI: 0.14-0.71). Conclusion: In patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionucleotide therapy plus SSA after SSA failure, the 'switch' strategy of SSA after progression improve progression-free survival and overall survival.

Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs / N. Prinzi, A. Raimondi, M. Maccauro, M. Milione, E. Garanzini, M. Torchio, F. Nichetti, G. Russo, L. Giacomelli, V. Mazzaferro, M. Bartolomeo, E. Seregni, F. Braud, S. Pusceddu. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 15:26(2019 Sep), pp. 3015-3024. [10.2217/fon-2019-0138]

Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs

M. Maccauro;E. Garanzini;F. Nichetti;V. Mazzaferro;F. Braud;S. Pusceddu
2019-09

Abstract

Aim: Data from 69 well-differentiated gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionucleotide therapy + somatostatin analogs (SSAs) after SSA treatment failure were evaluated. Methods: We identified two groups: S1 - patients who kept the same SSA treatment beyond progression; S2 - patients who switched the SSA with another SSA after progression. Results: Median progression-free survival was 53 and 127 months in S1 and S2, respectively (p = 0.001; hazard ratio: 0.31; 95% CI: 0.15-0.63). Median overall survival was 69 versus 150 months in S1 and S2, respectively (p = 0.004; hazard ratio: 0.32; 95% CI: 0.14-0.71). Conclusion: In patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionucleotide therapy plus SSA after SSA failure, the 'switch' strategy of SSA after progression improve progression-free survival and overall survival.
combinational therapy; gasto-entero-pancreatic neuroendocrine tumors; peptide receptor radionucleotide therapy; somatostatin analogues; switching strategy
Settore MED/06 - Oncologia Medica
Settore MED/18 - Chirurgia Generale
Article (author)
File in questo prodotto:
File Dimensione Formato  
Prinzi_Future Oncol.2019.pdf

non disponibili

Tipologia: Publisher's version/PDF
Dimensione 1.61 MB
Formato Adobe PDF
1.61 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/680534
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact